Clinical Trial Update: Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing pembrolizumab with external beam radiation therapy in relapsed or refractory non-Hodgkin lymphoma; the study (NCT03210662) has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Non-hodgkin Lymphoma
• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma
• T-cell Non-hodgkin Lymphoma
• Transformed Follicular Lymphoma to Diffuse Large B-cell Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2026-01-13